← Back to headlines
IGC Pharma Reports Q2 Results Amid Alzheimer's Trial Progress
IGC Pharma reported its Q2 2026 financial results, with GAAP EPS missing estimates but revenue beating expectations. The company also announced that its CALMA Alzheimer's trial is nearing enrollment closure.
17 Aug, 12:30 — 17 Aug, 13:27
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
morningstar
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
morningstar2h ago
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Morningstar
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure Morningstar
Read full article →seeking-alphaMixed1h ago
IGC Pharma GAAP EPS of -$0.03 misses by $0.01, revenue of $0.27M beats by $0.17M
Read full article →Coverage Timeline
First report: morningstar · 17 Aug, 12:30|Full coverage: 2 · 57m|Window: 57m
Left-leaningCenterRight-leaning
